Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 10, 2006, Pages 920-933

  Kyttälä, Aija ^a   Lahtinen, Ulla ^b   Braulke, Thomas ^c   Hofmann, Sandra L ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Batten disease; Lysosomal degradation; NCL; Neurodegeneration; Storage disease

Indexed keywords

BATTENIN; CATHEPSIN D; NEURONAL CEROID LIPOFUSCINOSIS 5 PROTEIN; NEURONAL CEROID LIPOFUSCINOSIS 6 PROTEIN; NEURONAL CEROID LIPOFUSCINOSIS 8 PROTEIN; PALMITOYL PROTEIN THIOESTERASE; PROTEIN; TRIPEPTIDYL PEPTIDASE I; UNCLASSIFIED DRUG;

BIOLOGY; HUMAN; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCREENING;

ANIMALS; CATHEPSINS; ENDOPEPTIDASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MOLECULAR CHAPERONES; MUTATION; NEURONAL CEROID-LIPOFUSCINOSES;

EID: 33750985356     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.05.007     Document Type: Review

References (204)

1. Cooper J.D. Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr. Opin. Neurol. 16 (2003) 121-128
2. Haltia M. The neuronal ceroid-lipofuscinoses. J. Neuropathol. Exp. Neurol. 62 (2003) 1-13
3. Mitchison H.M., Lim M.J., and Cooper J.D. Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol. 14 (2004) 86-96
4. Weimer J.M., Kriscenski-Perry E., Elshatory Y., and Pearce D.A. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. Neuromol. Med. 1 (2002) 111-124
5. Tyynela J., Sohar I., Sleat D.E., Gin R.M., Donnelly R.J., Baumann M., Haltia M., and Lobel P. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 19 (2000) 2786-2792
6. Koike M., Nakanishi H., Saftig P., Ezaki J., Isahara K., Ohsawa Y., Schulz-Schaeffer W., Watanabe T., Waguri S., Kametaka S., Shibata M., Yamamoto K., Kominami E., Peters C., von Figura K., and Uchiyama Y. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20 (2000) 6898-6906
7. Awano T., Katz M.L., O'Brien D.P., Taylor J.F., Evans J., Khan S., Sohar I., Lobel P., and Johnson G.S. A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. (2006) 341-348
8. Siintola E., Partanen S., Stromme P., Haapanen A., Haltia M., Maehlen J., Lehesjoki A.E., and Tyynela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain (2006)
9. Steinfeld R., Reinhardt K., Schreiber K., Hillebrand M., Kraetzner R., Bruck W., Saftig P., and Gartner J. Cathepsin d deficiency is associated with a human neurodegenerative disorder. Am. J. Hum. Genet. 78 (2006) 988-998
10. Felbor U., Kessler B., Mothes W., Goebel H.H., Ploegh H.L., Bronson R.T., and Olsen B.R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7883-7888
11. Koike M., Shibata M., Waguri S., Yoshimura K., Tanida I., Kominami E., Gotow T., Peters C., von Figura K., Mizushima N., Saftig P., and Uchiyama Y. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167 (2005) 1713-1728
12. Tang C.H., Lee J.W., Galvez M.G., Robillard L., Mole S.E., and Chapman H.A. Murine cathepsin f deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol. Cell. Biol. 26 (2006) 2309-2316
13. Yoshikawa M., Uchida S., Ezaki J., Rai T., Hayama A., Kobayashi K., Kida Y., Noda M., Koike M., Uchiyama Y., Marumo F., Kominami E., and Sasaki S. CLC-3 deficiency leads to phenotypes similar to human neuronal ceroid lipofuscinosis. Genes Cells 7 (2002) 597-605
14. Kasper D., Planells-Cases R., Fuhrmann J.C., Scheel O., Zeitz O., Ruether K., Schmitt A., Poet M., Steinfeld R., Schweizer M., Kornak U., and Jentsch T.J. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 24 (2005) 1079-1091
15. Vesa J., Hellsten E., Verkruyse L.A., Camp L.A., Rapola J., Santavuori P., Hofmann S.L., and Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376 (1995) 584-587
16. Camp L.A., and Hofmann S.L. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-Ras. J. Biol. Chem. 268 (1993) 22566-22574
17. Camp L.A., Verkruyse L.A., Afendis S.J., Slaughter C.A., and Hofmann S.L. Molecular cloning and expression of palmitoyl-protein thioesterase. J. Biol. Chem. 269 (1994) 23212-23219
18. Lu J.Y., Verkruyse L.A., and Hofmann S.L. Lipid thioesters derived from acylated proteins accumulate in infantile neuronal ceroid lipofuscinosis: correction of the defect in lymphoblasts by recombinant palmitoyl-protein thioesterase. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10046-10050
19. Lu J.Y., Verkruyse L.A., and Hofmann S.L. The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function. Biochim. Biophys. Acta 1583 (2002) 35-44
20. Smotrys J.E., and Linder M.E. Palmitoylation of intracellular signaling proteins: regulation and function. Annu. Rev. Biochem. 73 (2004) 559-587
21. Soyombo A.A., and Hofmann S.L. Molecular cloning and expression of palmitoyl-protein thioesterase 2 (PPT2), a homolog of lysosomal palmitoyl-protein thioesterase with a distinct substrate specificity. J. Biol. Chem. 272 (1997) 27456-27463
22. Soyombo A.A., Yi W., and Hofmann S.L. Structure of the human palmitoyl-protein thioesterase-2 gene (PPT2) in the major histocompatibility complex on chromosome 6p21.3. Genomics 56 (1999) 208-216
23. Gupta P., Soyombo A.A., Shelton J.M., Wilkofsky I.G., Wisniewski K.E., Richardson J.A., and Hofmann S.L. Disruption of PPT2 in mice causes an unusual lysosomal storage disorder with neurovisceral features. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12325-12330
24. Camp L.A., and Hofmann S.L. Assay and isolation of palmitoyl-protein thioesterase from bovine brain using palmitoylated H-Ras as substrate. Methods Enzymol. 250 (1995) 336-347
25. Das A.K., Bellizzi III J.J., Tandel S., Biehl E., Clardy J., and Hofmann S.L. Structural basis for the insensitivity of a serine enzyme (palmitoyl-protein thioesterase) to phenylmethylsulfonyl fluoride. J. Biol. Chem. 275 (2000) 23847-23851
26. Schriner J.E., Yi W., and Hofmann S.L. cDNA and genomic cloning of human palmitoyl-protein thioesterase (PPT), the enzyme defective in infantile neuronal ceroid lipofuscinosis. Genomics 34 (1996) 317-322
27. Verkruyse L.A., and Hofmann S.L. Lysosomal targeting of palmitoyl-protein thioesterase. J. Biol. Chem. 271 (1996) 15831-15836
28. Bellizzi III J.J., Widom J., Kemp C., Lu J.Y., Das A.K., Hofmann S.L., and Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4573-4578
29. Hellsten E., Vesa J., Olkkonen V.M., Jalanko A., and Peltonen L. Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. EMBO J. 15 (1996) 5240-5245
30. Sleat D.E., Sohar I., Lackland H., Majercak J., and Lobel P. Rat brain contains high levels of mannose-6-phosphorylated glycoproteins including lysosomal enzymes and palmitoyl-protein thioesterase, an enzyme implicated in infantile neuronal lipofuscinosis. J. Biol. Chem. 271 (1996) 19191-19198
31. Sleat D.E., Lackland H., Wang Y., Sohar I., Xiao G., Li H., and Lobel P. The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics 5 (2005) 1520-1532
32. Chataway T.K., Whittle A.M., Lewis M.D., Bindloss C.A., Davey R.C., Moritz R.L., Simpson R.J., Hopwood J.J., and Meikle P.J. Two-dimensional mapping and microsequencing of lysosomal proteins from human placenta. Placenta 19 (1998) 643-654
33. Garin J., Diez R., Kieffer S., Dermine J.F., Duclos S., Gagnon E., Sadoul R., Rondeau C., and Desjardins M. The phagosome proteome: insight into phagosome functions. J. Cell Biol. 152 (2001) 165-180
34. Fojan P., Jonson P.H., Petersen M.T., and Petersen S.B. What distinguishes an esterase from a lipase: a novel structural approach. Biochimie 82 (2000) 1033-1041
35. Jalanko A., Vesa J., Manninen T., von Schantz C., Minye H., Fabritius A.L., Salonen T., Rapola J., Gentile M., Kopra O., and Peltonen L. Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons. Neurobiol. Dis. 18 (2005) 226-241
36. Lian X., Yan C., Qin Y., Knox L., Li T., and Du H. Neutral lipids and peroxisome proliferator-activated receptor-{gamma} control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice. Am. J. Pathol. 167 (2005) 813-821
37. Dhami R., Passini M.A., and Schuchman E.H. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of Acid sphingomyelinase knockout mice. Mol. Ther. 13 (2006) 556-564
38. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., and Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1902-1907
39. Wada R., Tifft C.J., and Proia R.L. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10954-10959
40. Bible E., Gupta P., Hofmann S.L., and Cooper J.D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16 (2004) 346-359
41. Tyynela J., Baumann M., Henseler M., Sandhoff K., and Haltia M. Sphingolipid activator proteins in the neuronal ceroid-lipofuscinoses: an immunological study. Acta Neuropathol. (Berl.) 89 (1995) 391-398
42. Lu J.Y., and Hofmann S.L. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. J. Inherit. Metab. Dis. 29 (2006) 119-126
43. Cho S., and Dawson G. Palmitoyl protein thioesterase 1 protects against apoptosis mediated by Ras-Akt-caspase pathway in neuroblastoma cells. J. Neurochem. 74 (2000) 1478-1488
44. Cho S., Dawson P.E., and Dawson G. Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells. J. Neurosci. Res. 62 (2000) 234-240
45. Dawson G., Dawson S.A., Marinzi C., and Dawson P.E. Anti-tumor promoting effects of palmitoyl: protein thioesterase inhibitors against a human neurotumor cell line. Cancer Lett. 187 (2002) 163-168
46. Goswami R., Ahmed M., Kilkus J., Han T., Dawson S.A., and Dawson G. Differential regulation of ceramide in lipid-rich microdomains (rafts): antagonistic role of palmitoyl:protein thioesterase and neutral sphingomyelinase 2. J. Neurosci. Res. 81 (2005) 208-217
47. Riikonen R., Vanhanen S.L., Tyynela J., Santavuori P., and Turpeinen U. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology 54 (2000) 1828-1832
48. Korey C.A., and MacDonald M.E. An over-expression system for characterizing Ppt1 function in Drosophila. BMC Neurosci. 4 (2003) 30
49. Ahtiainen L., Van Diggelen O.P., Jalanko A., and Kopra O. Palmitoyl protein thioesterase 1 is targeted to the axons in neurons. J. Comp. Neurol. 455 (2003) 368-377
50. Heinonen O., Kyttala A., Lehmus E., Paunio T., Peltonen L., and Jalanko A. Expression of palmitoyl protein thioesterase in neurons. Mol. Genet. Metab. 69 (2000) 123-129
51. Lehtovirta M., Kyttala A., Eskelinen E.L., Hess M., Heinonen O., and Jalanko A. Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL). Hum. Mol. Genet. 10 (2001) 69-75
52. Virmani T., Gupta P., Liu X., Kavalali E.T., and Hofmann S.L. Progressively reduced synaptic vesicle pool size in cultured neurons derived from neuronal ceroid lipofuscinosis-1 knockout mice. Neurobiol. Dis. 20 (2005) 314-323
53. Gupta P., Soyombo A.A., Atashband A., Wisniewski K.E., Shelton J.M., Richardson J.A., Hammer R.E., and Hofmann S.L. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13566-13571
54. Zhang Z., Lee Y.C., Kim S.J., Choi M.S., Tsai P.C., Xu Y., Xiao Y.J., Zhang P., Heffer A., and Mukherjee A.B. Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. Hum. Mol. Genet. 15 (2006) 337-346
55. Harding H.P., Calfon M., Urano F., Novoa I., and Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18 (2002) 575-599
56. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005) 739-789
57. Tessitore A., del P.M.M., Sano R., Ma Y., Mann L., Ingrassia A., Laywell E.D., Steindler D.A., Hendershot L.M., and d'Azzo A. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15 (2004) 753-766
58. Sleat D.E., Donnelly R.J., Lackland H., Liu C.G., Sohar I., Pullarkat R.K., and Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277 (1997) 1802-1805
59. Sohar I., Sleat D.E., Jadot M., and Lobel P. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J. Neurochem. 73 (1999) 700-711
60. Rawlings N.D., and Barrett A.J. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta 1429 (1999) 496-500
61. Vines D.J., and Warburton M.J. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett. 443 (1999) 131-135
62. Vines D., and Warburton M.J. Purification and characterisation of a tripeptidyl aminopeptidase I from rat spleen. Biochim. Biophys. Acta 1384 (1998) 233-242
63. Tomkinson B. Tripeptidyl peptidases: enzymes that count. Trends Biochem. Sci. 24 (1999) 355-359
64. Doebber T.W., Divor A.R., and Ellis S. Identification of a tripeptidyl aminopeptidase in the anterior pituitary gland: effect on the chemical and biological properties of rat and bovine growth hormones. Endocrinology 103 (1978) 1794-1804
65. McDonald J.K., Hoisington A.R., and Eisenhauer D.A. Partial purification and characterization of an ovarian tripeptidyl peptidase: a lysosomal exopeptidase that sequentially releases collagen-related (Gly-Pro-X) triplets. Biochem. Biophys. Res. Commun. 126 (1985) 63-71
66. Andersen K.J., and McDonald J.K. Subcellular distribution of renal tripeptide-releasing exopeptidases active on collagen-like sequences. Am. J. Physiol. 252 (1987) F890-F898
67. Lin L., and Lobel P. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem. J. 357 (2001) 49-55
68. Tomkinson B., and Lindas A.C. Tripeptidyl-peptidase II: a multi-purpose peptidase. Int. J. Biochem. Cell Biol. 37 (2005) 1933-1937
69. Lin L., Sohar I., Lackland H., and Lobel P. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J. Biol. Chem. 276 (2001) 2249-2255
70. Golabek A.A., Wujek P., Walus M., Bieler S., Soto C., Wisniewski K.E., and Kida E. Maturation of human tripeptidyl-peptidase I in vitro. J. Biol. Chem. 279 (2004) 31058-31067
71. Ezaki J., Takeda-Ezaki M., Oda K., and Kominami E. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis. Biochem. Biophys. Res. Commun. 268 (2000) 904-908
72. Comellas-Bigler M., Fuentes-Prior P., Maskos K., Huber R., Oyama H., Uchida K., Dunn B.M., Oda K., and Bode W. The 1.4 a crystal structure of kumamolysin: a thermostable serine-carboxyl-type proteinase. Structure 10 (2002) 865-876
73. Wlodawer A., Li M., Dauter Z., Gustchina A., Uchida K., Oyama H., Dunn B.M., and Oda K. Carboxyl proteinase from Pseudomonas defines a novel family of subtilisin-like enzymes. Nat. Struct. Biol. 8 (2001) 442-446
74. Wlodawer A., Durell S.R., Li M., Oyama H., Oda K., and Dunn B.M. A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. BMC Struct. Biol. 3 (2003) 8
75. Oyama H., Fujisawa T., Suzuki T., Dunn B.M., Wlodawer A., and Oda K. Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2). J. Biochem. (Tokyo) 138 (2005) 127-134
76. Walus M., Kida E., Wisniewski K.E., and Golabek A.A. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I. FEBS Lett. 579 (2005) 1383-1388
77. Wujek P., Kida E., Walus M., Wisniewski K.E., and Golabek A.A. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I. J. Biol. Chem. 279 (2004) 12827-12839
78. Golabek A.A., Kida E., Walus M., Wujek P., Mehta P., and Wisniewski K.E. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. J. Biol. Chem. 278 (2003) 7135-7145
79. Tsiakas K., Steinfeld R., Storch S., Ezaki J., Lukacs Z., Kominami E., Kohlschutter A., Ullrich K., and Braulke T. Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity. Glycobiology 14 (2004) 1C-5C
80. Tian Y., Sohar I., Taylor J.W., and Lobel P. Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates. J. Biol. Chem. 281 (2006) 6559-6572
81. Watanabe Y., Kumagai Y., and Fujimoto Y. Acidic tripeptidyl aminopeptidase in rat liver tritosomes: partial purification and determination of its primary substrate specificity. Biochem. Int. 27 (1992) 869-877
82. Koike M., Shibata M., Ohsawa Y., Kametaka S., Waguri S., Kominami E., and Uchiyama Y. The expression of tripeptidyl peptidase I in various tissues of rats and mice. Arch. Histol. Cytol. 65 (2002) 219-232
83. Suopanki J., Partanen S., Ezaki J., Baumann M., Kominami E., and Tyynela J. Developmental changes in the expression of neuronal ceroid lipofuscinoses-linked proteins. Mol. Genet. Metab. 71 (2000) 190-194
84. Du P.G., Kato S., Li Y.H., Maeda T., Yamane T., Yamamoto S., Fujiwara M., Yamamoto Y., Nishi K., and Ohkubo I. Rat tripeptidyl peptidase I: molecular cloning, functional expression, tissue localization and enzymatic characterization. Biol. Chem. 382 (2001) 1715-1725
85. Kurachi Y., Oka A., Itoh M., Mizuguchi M., Hayashi M., and Takashima S. Distribution and development of CLN2 protein, the late-infantile neuronal ceroid lipofuscinosis gene product. Acta Neuropathol. (Berl.) 102 (2001) 20-26
86. Kida E., Golabek A.A., Walus M., Wujek P., Kaczmarski W., and Wisniewski K.E. Distribution of tripeptidyl peptidase I in human tissues under normal and pathological conditions. J. Neuropathol. Exp. Neurol. 60 (2001) 280-292
87. Chattopadhyay S., and Pearce D.A. Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3. Mol. Genet. Metab. 71 (2000) 207-211
88. Kopan S., Sivasubramaniam U., and Warburton M.J. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem. Biophys. Res. Commun. 319 (2004) 58-65
89. Bernardini F., and Warburton M.J. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis. Biochem. J. 366 (2002) 521-529
90. Warburton M.J., and Bernardini F. Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes. Neurosci. Lett. 331 (2002) 99-102
91. Palmer D.N., Fearnley I.M., Walker J.E., Hall N.A., Lake B.D., Wolfe L.S., Haltia M., Martinus R.D., and Jolly R.D. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am. J. Med. Genet. 42 (1992) 561-567
92. Ezaki J., Tanida I., Kanehagi N., and Kominami E. A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J. Neurochem. 72 (1999) 2573-2582
93. Ezaki J., Takeda-Ezaki M., and Kominami E. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. J. Biochem. (Tokyo) 128 (2000) 509-516
94. Kominami A.E. What are the requirements for lysosomal degradation of subunit c of mitochondrial ATPase?. IUBMB Life 54 (2002) 89-90
95. Holopainen J.M., Saarikoski J., Kinnunen P.K., and Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur. J. Biochem. 268 (2001) 5851-5856
96. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82 (1995) 949-957
97. Jarvela I., Sainio M., Rantamaki T., Olkkonen V.M., Carpen O., Peltonen L., and Jalanko A. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum. Mol. Genet. 7 (1998) 85-90
98. Kida E., Kaczmarski W., Golabek A.A., Kaczmarski A., Michalewski M., and Wisniewski K.E. Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro. Mol. Genet. Metab. 66 (1999) 265-271
99. Kremmidiotis G., Lensink I.L., Bilton R.L., Woollatt E., Chataway T.K., Sutherland G.R., and Callen D.F. The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. Hum. Mol. Genet. 8 (1999) 523-531
100. Persaud-Sawin D.A., McNamara II J.O., Rylova S., Vandongen A., and Boustany R.M. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr. Res. 56 (2004) 449-463
101. Katz M.L., Gao C.L., Prabhakaram M., Shibuya H., Liu P.C., and Johnson G.S. Immunochemical localization of the Batten disease (CLN3) protein in retina. Invest. Ophthalmol. Visual Sci. 38 (1997) 2375-2386
102. Rakheja D., Narayan S.B., Pastor J.V., and Bennett M.J. CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes). Biochem. Biophys. Res. Commun. 317 (2004) 988-991
103. Ezaki J., Takeda-Ezaki M., Koike M., Ohsawa Y., Taka H., Mineki R., Murayama K., Uchiyama Y., Ueno T., and Kominami E. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J. Neurochem. 87 (2003) 1296-1308
104. Kyttala A., Ihrke G., Vesa J., Schell M.J., and Luzio J.P. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol. Biol. Cell 15 (2004) 1313-1323
105. Jarvela I., Lehtovirta M., Tikkanen R., Kyttala A., and Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum. Mol. Genet. 8 (1999) 1091-1098
106. Luiro K., Kopra O., Lehtovirta M., and Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum. Mol. Genet. 10 (2001) 2123-2131
107. Haskell R.E., Carr C.J., Pearce D.A., Bennett M.J., and Davidson B.L. Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum. Mol. Genet. 9 (2000) 735-744
108. Janes R.W., Munroe P.B., Mitchison H.M., Gardiner R.M., Mole S.E., and Wallace B.A. A model for Batten disease protein CLN3: functional implications from homology and mutations. FEBS Lett. 399 (1996) 75-77
109. Fossale E., Wolf P., Espinola J.A., Lubicz-Nawrocka T., Teed A.M., Gao H., Rigamonti D., Cattaneo E., MacDonald M.E., and Cotman S.L. Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci. 5 (2004) 57
110. Das A.M., von Harlem R., Feist M., Lucke T., and Kohlschutter A. Altered levels of high-energy phosphate compounds in fibroblasts from different forms of neuronal ceroid lipofuscinoses: further evidence for mitochondrial involvement. Eur. J. Paediatr. Neurol. 5 Suppl. A (2001) 143-146
111. Cotman S.L., Vrbanac V., Lebel L.A., Lee R.L., Johnson K.A., Donahue L.R., Teed A.M., Antonellis K., Bronson R.T., Lerner T.J., and MacDonald M.E. Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11 (2002) 2709-2721
112. Narayan S.B., Pastor J.V., Mitchison H.M., and Bennett M.J. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease. Brain 127 (2004) 1748-1754
113. Pearce D.A., and Sherman F. A yeast model for the study of Batten disease. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6915-6918
114. Pearce D.A., and Sherman F. Investigation of Batten disease with the yeast Saccharomyces cerevisiae. Mol. Genet. Metab. 66 (1999) 314-319
115. Pearce D.A., Ferea T., Nosel S.A., Das B., and Sherman F. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet. 22 (1999) 55-58
116. Golabek A.A., Kida E., Walus M., Kaczmarski W., Michalewski M., and Wisniewski K.E. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol. Genet. Metab. 70 (2000) 203-213
117. Gachet Y., Codlin S., Hyams J.S., and Mole S.E. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis. J. Cell Sci. 118 (2005) 5525-5536
118. Ramirez-Montealegre D., and Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum. Mol. Genet. 14 (2005) 3759-3773
119. Padilla-Lopez S., and Pearce D.A. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity in order to regulate pH imbalance in the vacuole. J. Biol. Chem. 281 (2006) 10273-10280
120. Luiro K., Yliannala K., Ahtiainen L., Maunu H., Jarvela I., Kyttala A., and Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum. Mol. Genet. 13 (2004) 3017-3027
121. Mao Q., Foster B.J., Xia H., and Davidson B.L. Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett. 541 (2003) 40-46
122. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., and Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 447 (2004) 735-743
123. Kramer H., and Phistry M. Mutations in the Drosophila hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. J. Cell Biol. 133 (1996) 1205-1215
124. Kramer H., and Phistry M. Genetic analysis of hook, a gene required for endocytic trafficking in drosophila. Genetics 151 (1999) 675-684
125. Chattopadhyay S., and Pearce D.A. Interaction with Btn2p is required for localization of Rsglp: Btn2p-mediated changes in arginine uptake in Saccharomyces cerevisiae. Eukaryotic Cell 1 (2002) 606-612
126. Kim Y., Ramirez-Montealegre D., and Pearce D.A. A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15458-15462
127. Pisoni R.L., Thoene J.G., Lemons R.M., and Christensen H.N. Important differences in cationic amino acid transport by lysosomal system c and system y+ of the human fibroblast. J. Biol. Chem. 262 (1987) 15011-15018
128. Pearce D.A., McCall K., Mooney R.A., Chattopadhyay S., and Curran T.M. Altered amino acid levels in sera of a mouse model for juvenile neuronal ceroid lipofuscinoses. Clin. Chim. Acta 332 (2003) 145-148
129. Lange P.S., Langley B., Lu P., and Ratan R.R. Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J. Nutr. 134 (2004) 2812S-2817S (discussion 2818S-2819S)
130. Chattopadhyay S., Ito M., Cooper J.D., Brooks A.I., Curran T.M., Powers J.M., and Pearce D.A. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11 (2002) 1421-1431
131. Kim Y., Chattopadhyay S., Locke S., and Pearce D.A. Interaction among Btn1p, Btn2p, and Ist2p reveals potential interplay among the vacuole, amino acid levels, and ion homeostasis in the yeast Saccharomyces cerevisiae. Eukaryotic Cell 4 (2005) 281-288
132. Vesa J., Chin M.H., Oelgeschlager K., Isosomppi J., DellAngelica E.C., Jalanko A., and Peltonen L. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. Mol. Biol. Cell 13 (2002) 2410-2420
133. Storch S., Pohl S., and Braulke T. A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for efficient lysosomal targeting. J. Biol. Chem. 279 (2004) 53625-53634
134. Kyttala A., Yliannala K., Schu P., Jalanko A., and Luzio J.P. AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J. Biol. Chem. 280 (2005) 10277-10283
135. Weimer J.M., Custer A.W., Benedict J.W., Alexander N.A., Kingsley E., Federoff H.J., Cooper J.D., and Pearce D.A. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 22 (2006) 284-293
136. Walenta J.H., Didier A.J., Liu X., and Kramer H. The Golgi-associated hook3 protein is a member of a novel family of microtubule-binding proteins. J. Cell Biol. 152 (2001) 923-934
137. Weimer J.M., Chattopadhyay S., Custer A.W., and Pearce D.A. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. Biochem. Biophys. Res. Commun. 330 (2005) 1176-1181
138. Hryniewicz-Jankowska A., Czogalla A., Bok E., and Sikorsk A.F. Ankyrins, multifunctional proteins involved in many cellular pathways. Folia Histochem. Cytobiol. 40 (2002) 239-249
139. Roy S., Zhang B., Lee V.M., and Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. (Berl.) 109 (2005) 5-13
140. Lane S.C., Jolly R.D., Schmechel D.E., Alroy J., and Boustany R.M. Apoptosis as the mechanism of neurodegeneration in Batten's disease. J. Neurochem. 67 (1996) 677-683
141. Seigel G.M., Lotery A., Kummer A., Bernard D.J., Greene N.D., Turmaine M., Derksen T., Nussbaum R.L., Davidson B., Wagner J., and Mitchison H.M. Retinal pathology and function in a Cln3 knockout mouse model of juvenile neuronal ceroid lipofuscinosis (Batten disease). Mol. Cell. Neurosci. 19 (2002) 515-527
142. Persaud-Sawin D.A., and Boustany R.M. Cell death pathways in juvenile Batten disease. Apoptosis 10 (2005) 973-985
143. Persaud-Sawin D.A., VanDongen A., and Boustany R.M. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum. Mol. Genet. 11 (2002) 2129-2142
144. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., and Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 66 (1999) 294-308
145. Rylova S.N., Amalfitano A., Persaud-Sawin D.A., Guo W.X., Chang J., Jansen P.J., Proia A.D., and Boustany R.M. The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 62 (2002) 801-808
146. Savukoski M., Klockars T., Holmberg V., Santavuori P., Lander E.S., and Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat. Genet. 19 (1998) 286-288
147. Isosomppi J., Vesa J., Jalanko A., and Peltonen L. Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein. Hum. Mol. Genet. 11 (2002) 885-891
148. Kollmann K., Mutenda K.E., Balleininger M., Eckermann E., von Figura K., Schmidt B., and Lubke T. Identification of novel lysosomal matrix proteins by proteome analysis. Proteomics 5 (2005) 3966-3978
149. Tyynela J., Suopanki J., Santavuori P., Baumann M., and Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J. Neuropathol. Exp. Neurol. 56 (1997) 369-375
150. Holmberg V., Jalanko A., Isosomppi J., Fabritius A.L., Peltonen L., and Kopra O. The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the
151. Kopra O., Vesa J., von Schantz C., Manninen T., Minye H., Fabritius A.L., Rapola J., van Diggelen O.P., Saarela J., Jalanko A., and Peltonen L. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging. Hum. Mol. Genet. 13 (2004) 2893-2906
152. Gao H., Boustany R.M., Espinola J.A., Cotman S.L., Srinidhi L., Antonellis K.A., Gillis T., Qin X., Liu S., Donahue L.R., Bronson R.T., Faust J.R., Stout D., Haines J.L., Lerner T.J., and MacDonald M.E. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am. J. Hum. Genet. 70 (2002) 324-335
153. Wheeler R.B., Sharp J.D., Schultz R.A., Joslin J.M., Williams R.E., and Mole S.E. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am. J. Hum. Genet. 70 (2002) 537-542
154. Heine C., Koch B., Storch S., Kohlschutter A., Palmer D.N., and Braulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J. Biol. Chem. 279 (2004) 22347-22352
155. Mole S.E., Michaux G., Codlin S., Wheeler R.B., Sharp J.D., and Cutler D.F. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp. Cell Res. 298 (2004) 399-406
156. Bronson R.T., Donahue L.R., Johnson K.R., Tanner A., Lane P.W., and Faust J.R. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am. J. Med. Genet. 77 (1998) 289-297
157. Jolly R.D., Shimada A., Dopfmer I., Slack P.M., Birtles M.J., and Palmer D.N. Ceroid-lipofuscinosis (Batten's disease): pathogenesis and sequential neuropathological changes in the ovine model. Neuropathol. Appl. Neurobiol. 15 (1989) 371-383
158. Oswald M.J., Palmer D.N., Kay G.W., Shemilt S.J., Rezaie P., and Cooper J.D. Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol. Dis. 20 (2005) 49-63
159. Heine C., Tyynela J., Cooper J.D., Palmer D.N., Elleder M., Kohlschutter A., and Braulke T. Enhanced expression of manganese-dependent superoxide dismutase in human and sheep CLN6 tissues. Biochem. J. 376 (2003) 369-376
160. Yoshioka T., Homma T., Meyrick B., Takeda M., Moore-Jarrett T., Kon V., and Ichikawa I. Oxidants induce transcriptional activation of manganese superoxide dismutase in glomerular cells. Kidney Int. 46 (1994) 405-413
161. Visner G.A., Dougall W.C., Wilson J.M., Burr I.A., and Nick H.S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J. Biol. Chem. 265 (1990) 2856-2864
162. Hirvasniemi A., and Karumo J. Neuroradiological findings in the northern epilepsy syndrome. Acta Neurol. Scand. 90 (1994) 388-393
163. Hirvasniemi A., Herrala P., and Leisti J. Northern epilepsy syndrome: clinical course and the effect of medication on seizures. Epilepsia 36 (1995) 792-797
164. Ranta S., Zhang Y., Ross B., Lonka L., Takkunen E., Messer A., Sharp J., Wheeler R., Kusumi K., Mole S., Liu W., Soares M.B., Bonaldo M.F., Hirvasniemi A., de la Chapelle A., Gilliam T.C., and Lehesjoki A.E. The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat. Genet. 23 (1999) 233-236
165. Lonka L., Aalto A., Kopra O., Kuronen M., Kokaia Z., Saarma M., and Lehesjoki A.E. The neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated in mouse brain and up-regulated in the hippocampal kindling model of epilepsy. BMC Neurosci. 6 (2005) 27
166. Lonka L., Kyttala A., Ranta S., Jalanko A., and Lehesjoki A.E. The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. Hum. Mol. Genet. 9 (2000) 1691-1697
167. Lonka L., Salonen T., Siintola E., Kopra O., Lehesjoki A.E., and Jalanko A. Localization of wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in non-neuronal and neuronal cells. J. Neurosci. Res. 76 (2004) 862-871
168. Winter E., and Ponting C.P. TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing domains?. Trends Biochem. Sci. 27 (2002) 381-383
169. Hegde R.S., Voigt S., Rapoport T.A., and Lingappa V.R. TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum. Cell 92 (1998) 621-631
170. Barz W.P., and Walter P. Two endoplasmic reticulum (ER) membrane proteins that facilitate ER-to-Golgi transport of glycosylphosphatidylinositol-anchored proteins. Mol. Biol. Cell 10 (1999) 1043-1059
171. Heinrich S.U., Mothes W., Brunner J., and Rapoport T.A. The Sec61p complex mediates the integration of a membrane protein by allowing lipid partitioning of the transmembrane domain. Cell 102 (2000) 233-244
172. Guillas I., Kirchman P.A., Chuard R., Pfefferli M., Jiang J.C., Jazwinski S.M., and Conzelmann A. C26-CoA-dependent ceramide synthesis of Saccharomyces cerevisiae is operated by Lag1p and Lac1p. EMBO J. 20 (2001) 2655-2665
173. Schorling S., Vallee B., Barz W.P., Riezman H., and Oesterhelt D. Lag1p and Lac1p are essential for the Acyl-CoA-dependent ceramide synthase reaction in Saccharomyces cerevisiae. Mol. Biol. Cell 12 (2001) 3417-3427
174. Mizutani Y., Kihara A., and Igarashi Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem. J. 390 (2005) 263-271
175. Riebeling C., Allegood J.C., Wang E., Merrill Jr. A.H., and Futerman A.H. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 278 (2003) 43452-43459
176. Venkataraman K., Riebeling C., Bodennec J., Riezman H., Allegood J.C., Sullards M.C., Merrill Jr. A.H., and Futerman A.H. Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J. Biol. Chem. 277 (2002) 35642-35649
177. Schulz A., Dhar S., Rylova S., Dbaibo G., Alroy J., Hagel C., Artacho I., Kohlschutter A., Lin S., and Boustany R.M. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann. Neurol. 56 (2004) 342-350
178. Schulz A., Mousallem T., Venkataramani M., Persaud-Sawin D.A., Zucker A., Luberto C., Bielawska A., Bielawski J., Holthuis J.C., Jazwinski S.M., Kozhaya L., Dbaibo G.S., and Boustany R.M. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem. 281 (2006) 2784-2794
179. Hermansson M., Kakela R., Berghall M., Lehesjoki A.E., Somerharju P., and Lahtinen U. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation. EPMR, brain: a case study. J. Neurochem. 95 (2005) 609-617
180. Kakela R., Somerharju P., and Tyynela J. Analysis of phospholipid molecular species in brains from patients with infantile and juvenile neuronal-ceroid lipofuscinosis using liquid chromatography-electrospray ionization mass spectrometry. J. Neurochem. 84 (2003) 1051-1065
181. Messer A., and Flaherty L. Autosomal dominance in a late-onset motor neuron disease in the mouse. J. Neurogenet. 3 (1986) 345-355
182. Vance J.E., Stone S.J., and Faust J.R. Abnormalities in mitochondria-associated membranes and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta 1344 (1997) 286-299
183. Griffin J.L., Muller D., Woograsingh R., Jowatt V., Hindmarsh A., Nicholson J.K., and Martin J.E. Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics. Physiol. Genomics 11 (2002) 195-203
184. Bertamini M., Marzani B., Guarneri R., Guarneri P., Bigini P., Mennini T., and Curti D. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur. J. Neurosci. 16 (2002) 2291-2296
185. Guarneri R., Russo D., Cascio C., D'Agostino S., Galizzi G., Bigini P., Mennini T., and Guarneri P. Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis. Brain Res. 1014 (2004) 209-220
186. Battaglioli G., Martin D.L., Plummer J., and Messer A. Synaptosomal glutamate uptake declines progressively in the spinal cord of a mutant mouse with motor neuron disease. J. Neurochem. 60 (1993) 1567-1569
187. Mennini T., Bastone A., Crespi D., Comoletti D., and Manzoni C. Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice. J. Neurol. Sci. 157 (1998) 31-36
188. Mennini T., Bigini P., Ravizza T., Vezzani A., Calvaresi N., Tortarolo M., and Bendotti C. Expression of glutamate receptor subtypes in the spinal cord of control and mnd mice, a model of motor neuron disorder. J. Neurosci. Res. 70 (2002) 553-560
189. Koike M., Shibata M., Ohsawa Y., Nakanishi H., Koga T., Kametaka S., Waguri S., Momoi T., Kominami E., Peters C., Figura K., Saftig P., and Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol. Cell. Neurosci. 22 (2003) 146-161
190. Saftig P., Hetman M., Schmahl W., Weber K., Heine L., Mossmann H., Koster A., Hess B., Evers M., von Figura K., et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14 (1995) 3599-3608
191. Myllykangas L., Tyynela J., Page-McCaw A., Rubin G.M., Haltia M.J., and Feany M.B. Cathepsin d-deficient Drosophila recapitulate the key features of neuronal ceroid lipofuscinoses. Neurobiol. Dis. 19 (2005) 194-199
192. Augereau P., Miralles F., Cavailles V., Gaudelet C., Parker M., and Rochefort H. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol. Endocrinol. 8 (1994) 693-703
193. Tang J., and Wong R.N. Evolution in the structure and function of aspartic proteases. J. Cell. Biochem. 33 (1987) 53-63
194. Erickson A.H., Conner G.E., and Blobel G. Biosynthesis of a lysosomal enzyme. Partial structure of two transient and functionally distinct NH2-terminal sequences in cathepsin D. J. Biol. Chem. 256 (1981) 11224-11231
195. Gieselmann V., Pohlmann R., Hasilik A., and Von Figura K. Biosynthesis and transport of cathepsin D in cultured human fibroblasts. J. Cell Biol. 97 (1983) 1-5
196. Hasilik A., and Neufeld E.F. Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J. Biol. Chem. 255 (1980) 4937-4945
197. Rijnboutt S., Stoorvogel W., Geuze H.J., and Strous G.J. Identification of subcellular compartments involved in biosynthetic processing of cathepsin D. J. Biol. Chem. 267 (1992) 15665-15672
198. Gieselmann V., Hasilik A., and von Figura K. Processing of human cathepsin D in lysosomes in vitro. J. Biol. Chem. 260 (1985) 3215-3220
199. Kobayashi T., Honke K., Gasa S., Fujii T., Maguchi S., Miyazaki T., and Makita A. Proteolytic processing sites producing the mature form of human cathepsin D. Int. J. Biochem. 24 (1992) 1487-1491
200. Storch S., and Braulke T. Transport of lysosomal enzymes. In: Saftig P. (Ed). Lysosomes, Eurekah Landes Bioscience (2005), Springer and Business media, New York 17-26
201. Metcalf P., and Fusek M. Two crystal structures for cathepsin D: the lysosomal targeting signal and active site. EMBO J. 12 (1993) 1293-1302
202. Junaid M.A., and Pullarkat R.K. Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases. Neurosci. Lett. 264 (1999) 157-160
203. Dhar S., Bitting R.L., Rylova S.N., Jansen P.J., Lockhart E., Koeberl D.D., Amalfitano A., and Boustany R.M. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann. Neurol. 51 (2002) 448-466
204. Stroikin Y., Dalen H., Loof S., and Terman A. Inhibition of autophagy with 3-methyladenine results in impaired turnover of lysosomes and accumulation of lipofuscin-like material. Eur. J. Cell Biol. 83 (2004) 583-590